{"DataElement":{"publicId":"13382781","version":"1","preferredName":"BRCA Gene Mutation Stratification Factors Code","preferredDefinition":"Coded response representing the protocol stratification factors of individuals with a mutation in the nucleotide sequence of BRCA1 or BRCA2 genes.","longName":"3289550v1.00:13382778v1.00","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"3289550","version":"1","preferredName":"Person Clinical Trial BRCA1 Mutation BRCA2 Mutation Stratification","preferredDefinition":"information related to the process of classifying patients, with mutation that is typically a heritable, permanent change in the nucleotide sequence of the either BRCA1 or BRCA2 genes, who are participating in the type of research study that tests how well new medical treatments or other interventions work.","longName":"2236731v1.0:3289548v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3289565","version":"1","preferredName":"Clinical Trial BRCA1 Mutation BRCA2 Mutation Stratification","preferredDefinition":"A type of research study that tests how well new medical treatments or other interventions work in people.  Such studies test new methods of screening, prevention, diagnosis, or treatment of a disease.  The study may be carried out in a clinic or other medical facility.  Also called a clinical study.:A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.:A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.:The process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"C15207:C19635:C19636:C25689","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial","conceptCode":"C15207","definition":"A type of research study that tests how well new medical treatments or other interventions work in people.  Such studies test new methods of screening, prevention, diagnosis, or treatment of a disease.  The study may be carried out in a clinic or other medical facility.  Also called a clinical study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"BRCA1 Gene Mutation","conceptCode":"C19635","definition":"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"BRCA2 Gene Mutation","conceptCode":"C19636","definition":"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stratification","conceptCode":"C25689","definition":"The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE9028DE-5983-8BC2-E040-BB89AD4348AC","latestVersionIndicator":"Yes","beginDate":"2011-10-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-05","modifiedBy":"ONEDATA","dateModified":"2011-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE9028DE-581D-8BC2-E040-BB89AD4348AC","latestVersionIndicator":"Yes","beginDate":"2011-10-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13382778","version":"1","preferredName":"BRCA Gene Mutation Stratification Factors Code","preferredDefinition":"A change in the nucleotide sequence of a gene in the BRCA family._Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"13382778v1.00","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"2","valueDescription":null,"ValueMeaning":{"publicId":"13382779","version":"1","preferredName":"BRCA1 Gene Mutation Stratification Factors","longName":"13382779v1.00","preferredDefinition":"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers._Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRCA1 Gene Mutation","conceptCode":"C19635","definition":"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA1 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA1 gene. Approximately 75% of these alterations result in a truncated form of the breast cancer type 1 susceptibility protein. Mutations in the BRCA1 gene predispose individuals to breast and ovarian cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stratification Factors","conceptCode":"C16153","definition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B9D677-E4A8-2E42-E053-731AD00A1525","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B9D677-E4AA-2E42-E053-731AD00A1525","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-04-19","deletedIndicator":"No"},{"value":"1","valueDescription":null,"ValueMeaning":{"publicId":"13382780","version":"1","preferredName":"BRCA2 Gene Mutation Stratification Factors","longName":"13382780v1.00","preferredDefinition":"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer._Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRCA2 Gene Mutation","conceptCode":"C19636","definition":"A mutation that is typically a heritable, permanent change in the nucleotide sequence of the BRCA2 gene. Single nucleotide substitutions and small deletions or insertions (1-20 bases) account for the majority of mutations in the BRCA2 gene. Most of these alterations result in a truncated form of the breast cancer type 2 susceptibility protein. Mutations in the BRCA2 gene predispose males to breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stratification Factors","conceptCode":"C16153","definition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B9D677-E4A9-2E42-E053-731AD00A1525","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F9B9D677-E4AB-2E42-E053-731AD00A1525","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-04-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13382777","version":"1","preferredName":"BRCA Gene Mutation Stratification Factors Code","preferredDefinition":"A change in the nucleotide sequence of a gene in the BRCA family._Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"13382777v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRCA Gene Mutation","conceptCode":"C179406","definition":"A change in the nucleotide sequence of a gene in the BRCA family.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stratification Factors","conceptCode":"C16153","definition":"Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B9CA4B-91BA-2C6D-E053-731AD00AD37E","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B9CA4B-91BB-2C6D-E053-731AD00AD37E","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"BRCA_MUT_STRAT_CODE","type":"OID, SWOG","context":"SWOG"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"BRCA Mutation Status","url":null,"context":"SWOG"},{"name":"SWOG CRF TEXT 1","type":"Alternate Question Text","description":"Which mutation in the BRCA1/BRCA2 gene is present in the participant?","url":null,"context":"SWOG"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B9EB36-F30F-3991-E053-731AD00A02BA","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}